Literature DB >> 16611348

Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab.

A D Kirk, D A Hale, S J Swanson, R B Mannon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16611348     DOI： 10.1111/j.1600-6143.2006.01258.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   8.086


× No keyword cloud information.
  15 in total

1.  Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.

Authors:  Phillip Scheinberg; Olga Nunez; Barbara Weinstein; Priscila Scheinberg; Colin O Wu; Neal S Young
Journal:  Blood       Date:  2011-11-08       Impact factor: 22.113

Review 2.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

3.  Antibody induction therapy in adult kidney transplantation: A controversy continues.

Authors:  Kanwaljit K Chouhan; Rubin Zhang
Journal:  World J Transplant       Date:  2012-04-24

Review 4.  Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.

Authors:  Jurgen Sota; Donato Rigante; Giuseppe Lopalco; Bruno Frediani; Rossella Franceschini; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Claudia Fabiani; Luca Cantarini
Journal:  Rheumatol Int       Date:  2017-07-27       Impact factor: 2.631

Review 5.  2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.

Authors:  Ilaria Muller; Carla Moran; Beatriz Lecumberri; Brigitte Decallonne; Neil Robertson; Joanne Jones; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2019-07-04

Review 6.  Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.

Authors:  Yi-chi M Kong; Wei-Zen Wei; Yaron Tomer
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

7.  Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.

Authors:  L Scappaticcio; M Castellana; C Virili; G Bellastella; M Centanni; S Cannavò; A Campennì; R M Ruggeri; L Giovanella; P Trimboli
Journal:  J Endocrinol Invest       Date:  2019-08-26       Impact factor: 4.256

Review 8.  Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy.

Authors:  Joshua M Rosenblum; Allan D Kirk
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

9.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

10.  BAFF is increased in renal transplant patients following treatment with alemtuzumab.

Authors:  D Bloom; Z Chang; K Pauly; J Kwun; J Fechner; C Hayes; M Samaniego; S Knechtle
Journal:  Am J Transplant       Date:  2009-06-12       Impact factor: 8.086
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.